Phase 2 Peritoneal Cancer Clinical Trials
19 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–19 of 19 trials
Recruiting
Phase 2
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc310 enrolled91 locationsNCT05128825
Recruiting
Phase 1Phase 2
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting
Phase 2
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 2
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Fallopian Tube CancerOvary CancerPeritoneal Cancer
University of Colorado, Denver53 enrolled5 locationsNCT05887609
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 2
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Ovarian CancerOvarian CarcinomaFallopian Tube Cancer+7 more
Memorial Sloan Kettering Cancer Center86 enrolled7 locationsNCT06290193
Recruiting
Phase 1Phase 2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting
Phase 2Phase 3
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers
N.N. Alexandrov National Cancer Centre120 enrolled1 locationNCT07472140
Recruiting
Phase 2
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Stage IV Ovarian Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8+3 more
Mayo Clinic43 enrolled1 locationNCT05465941
Recruiting
Phase 1Phase 2
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Primary Peritoneal CancerFallopian Tube CancersFIGO Stage III and IV Ovarian Cancer
TORL Biotherapeutics, LLC60 enrolled1 locationNCT07322094
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer+2 more
Regeneron Pharmaceuticals890 enrolled51 locationsNCT03564340
Recruiting
Phase 1Phase 2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ovarian CancerEndometrial CancerPrimary Peritoneal Cancer+1 more
Regeneron Pharmaceuticals612 enrolled24 locationsNCT04590326
Recruiting
Phase 2
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube
University of Alabama at Birmingham70 enrolled9 locationsNCT04606914
Recruiting
Phase 2
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
The University of Hong Kong18 enrolled1 locationNCT07022535
Recruiting
Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Alexander B Olawaiye, MD33 enrolled1 locationNCT05071937
Recruiting
Phase 2
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Qilu Hospital of Shandong University105 enrolled1 locationNCT06735326
Recruiting
Phase 2
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Ovarian CancerEndometrial CancerPrimary Peritoneal Cancer+1 more
Hansoh BioMedical R&D Company460 enrolled28 locationsNCT06014190
Recruiting
Phase 2
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
Ovarian CancerFallopian Tube CancerOvary Cancer+4 more
University College, London80 enrolled1 locationNCT05080556
Completed
Phase 2
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form and Oral Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin, Carboplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-Refractory or Resistant.
Recurrent, late-stage epithelial ovarian cancer or primary peritoneal cancer that is refractory or resistant to taxanes and/or platinums.
Marshall Edwards Pty Ltd100 enrolled1 locationACTRN12605000432617